Literature DB >> 23098178

Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes.

Diana E Ayala1, Ana Moyá, Juan J Crespo, Carmen Castiñeira, Manuel Domínguez-Sardiña, Sonia Gomara, Elvira Sineiro, Artemio Mojón, María J Fontao, Ramón C Hermida.   

Abstract

There is strong association between diabetes and increased risk of end-organ damage, stroke, and cardiovascular disease (CVD) morbidity and mortality. Non-dipping (<10% decline in the asleep relative to awake blood pressure [BP] mean), as determined by ambulatory BP monitoring (ABPM), is frequent in diabetes and consistently associated with increased CVD risk. The reported prevalence of non-dipping in diabetes is highly variable, probably due to differences in the study groups (normotensive subjects, untreated hypertensives, treated hypertensives), relatively small sample sizes, reliance only on a single, low-reproducibility, 24-h ABPM evaluation per participant, and definition of daytime and nighttime periods by arbitrary selected fixed clock-hour spans. Accordingly, we evaluated the influence of diabetes on the circadian BP pattern by 48-h ABPM (rather than for 24 h to increase reproducibility of results) during which participants maintained a diary listing times of going to bed at night and awakening in the morning. This cross-sectional study involved 12 765 hypertensive patients (6797 men/5968 women), 58.1 ± 14.1 (mean ± SD) yrs of age, enrolled in the Hygia Project, designed to evaluate prospectively CVD risk by ABPM in primary care centers of northwest Spain. Among the participants, 2954 (1799 men/1155 women) had type 2 diabetes. At the time of study, 525/3314 patients with/without diabetes were untreated for hypertension, and the remaining 2429/6497 patients with/without diabetes were treated. Hypertension was defined as awake systolic (SBP)/diastolic (DBP) BP mean ≥135/85 mm Hg, or asleep SBP/DBP mean ≥120/70 mm Hg, or BP-lowering treatment. Hypertensive patients with than without diabetes were more likely to be men and of older age, have diagnoses of microalbuminuria, proteinuria, chronic kidney disease, obstructive sleep apnea, metabolic syndrome, and/or obesity, plus higher glucose, creatinine, uric acid, and triglycerides, but lower cholesterol and estimated glomerular filtration rate. In patients with diabetes, ambulatory SBP was significantly elevated (p < .001), mainly during the hours of nighttime sleep and initial hours after morning awakening, independent of presence/absence of BP-lowering treatment. Ambulatory DBP, however, was significantly higher (p < .001) in patients without diabetes, mainly during the daytime. Differing trends for SBP and DBP between groups resulted in large differences in ambulatory pulse pressure (PP), it being significantly greater (p < .001) throughout the entire 24 h in patients with diabetes, even after correcting for age. Prevalence of non-dipping was significantly higher in patients with than without diabetes (62.1% vs. 45.9%; p < .001). Largest difference between groups was in the prevalence of the riser BP pattern, i.e., asleep SBP mean greater than awake SBP mean (19.9% vs. 8.1% in patients with and without diabetes, respectively; p < .001). Elevated asleep SBP mean was the major basis for the diagnosis of hypertension and/or inadequate BP control among patients with diabetes; thus, among the uncontrolled hypertensive patients with diabetes, 89.2% had nocturnal hypertension. Our findings document significantly elevated prevalence of a blunted nocturnal BP decline in hypertensive patients with diabetes. Most important, prevalence of the riser BP pattern, associated with highest CVD risk among all possible BP patterns, was more than twice as prevalent in diabetes. Patients with diabetes also presented significantly elevated ambulatory PP, reflecting increased arterial stiffness and enhanced CVD risk. These collective findings indicate that diabetes should be included among the clinical conditions for which ABPM is recommended for proper CVD risk assessment.

Entities:  

Mesh:

Year:  2012        PMID: 23098178     DOI: 10.3109/07420528.2012.701489

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  34 in total

1.  Elevated asleep BP as predictor of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-12-07       Impact factor: 10.122

2.  Nighttime BP in Elderly Individuals with Prediabetes/Diabetes with and without CKD: The HEIJO-KYO Study.

Authors:  Kenji Obayashi; Keigo Saeki; Norio Kurumatani
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-25       Impact factor: 8.237

Review 3.  Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA.

Authors:  Dorrin Zarrin Khat; Mansoor Husain
Journal:  Curr Diab Rep       Date:  2018-06-09       Impact factor: 4.810

Review 4.  Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Juan J Crespo; María T Ríos; Ana Moyá; Francesco Portaluppi
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 5.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

Review 6.  Mechanism of the circadian clock in physiology.

Authors:  Jacob Richards; Michelle L Gumz
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-04-10       Impact factor: 3.619

Review 7.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

Review 8.  Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction.

Authors:  R C Hermida; D E Ayala; A Mojón; M H Smolensky; F Portaluppi; J R Fernández
Journal:  J Hum Hypertens       Date:  2014-02-06       Impact factor: 3.012

9.  Chronic Heart Failure Abolishes Circadian Rhythms in Resting and Chemoreflex Breathing.

Authors:  Robert Lewis; Bryan T Hackfort; Harold D Schultz
Journal:  Adv Exp Med Biol       Date:  2018       Impact factor: 2.622

Review 10.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Francesco Portaluppi
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.